Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Autolus Therapeutics Plc ADR (AUTL)

Autolus Therapeutics Plc ADR (AUTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 447,120
  • Shares Outstanding, K 266,143
  • Annual Sales, $ 10,120 K
  • Annual Income, $ -220,660 K
  • EBIT $ -263 M
  • EBITDA $ -255 M
  • 60-Month Beta 2.01
  • Price/Sales 43.13
  • Price/Cash Flow N/A
  • Price/Book 1.64

Options Overview Details

View History
  • Implied Volatility 483.63% (-25.71%)
  • Historical Volatility 74.52%
  • IV Percentile 94%
  • IV Rank 65.82%
  • IV High 697.19% on 11/10/25
  • IV Low 72.43% on 05/20/25
  • Expected Move (DTE 21) 0.1700 (10.12%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4
  • Volume Avg (30-Day) 383
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 14,431
  • Open Int (30-Day) 19,871
  • Expected Range 1.5100 to 1.8500

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.32
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -177.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +28.24%
on 12/02/25
1.7900 -6.15%
on 12/22/25
+0.4400 (+35.48%)
since 11/24/25
3-Month
1.2000 +40.00%
on 11/21/25
1.8000 -6.67%
on 10/09/25
+0.1200 (+7.69%)
since 09/24/25
52-Week
1.1050 +52.04%
on 04/11/25
2.8000 -40.00%
on 01/03/25
-0.5700 (-25.33%)
since 12/24/24

Most Recent Stories

More News
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cells All patients show deep B-cell...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6800 (+2.44%)
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Company reports Q3 2025 AUCATZYL ® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of target Clinical execution and data generation...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

LONDON & GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase...

AUTL : 1.6800 (+2.44%)
Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation...

AUTL : 1.6800 (+2.44%)

Business Summary

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London,...

See More

Key Turning Points

3rd Resistance Point 1.7633
2nd Resistance Point 1.7267
1st Resistance Point 1.7033
Last Price 1.6800
1st Support Level 1.6433
2nd Support Level 1.6067
3rd Support Level 1.5833

See More

52-Week High 2.8000
Fibonacci 61.8% 2.1525
Fibonacci 50% 1.9525
Fibonacci 38.2% 1.7525
Last Price 1.6800
52-Week Low 1.1050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar